Press coverage about Quidel (NASDAQ:QDEL) has trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quidel earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.8292472304878 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of equities research analysts have recently issued reports on QDEL shares. Zacks Investment Research cut Quidel from a “hold” rating to a “strong sell” rating in a report on Thursday, December 28th. Canaccord Genuity restated a “buy” rating and set a $48.00 price objective on shares of Quidel in a report on Wednesday, October 25th. CL King upgraded Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a report on Thursday, January 4th. Piper Jaffray Companies restated a “buy” rating and set a $50.00 price objective on shares of Quidel in a report on Thursday, December 14th. Finally, Barclays boosted their price objective on Quidel from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $50.00.
Shares of Quidel (NASDAQ:QDEL) opened at $45.99 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel has a 1 year low of $18.25 and a 1 year high of $47.60. The firm has a market cap of $1,560.00, a P/E ratio of -287.44, a PEG ratio of 1.48 and a beta of 1.15.
In other Quidel news, SVP Werner Kroll sold 7,565 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $39.50, for a total transaction of $298,817.50. Following the completion of the transaction, the senior vice president now directly owns 10,261 shares in the company, valued at $405,309.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Robert Joseph Bujarski sold 110,704 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $39.78, for a total transaction of $4,403,805.12. Following the transaction, the senior vice president now owns 79,797 shares of the company’s stock, valued at $3,174,324.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 385,790 shares of company stock valued at $15,760,155. 22.00% of the stock is owned by company insiders.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.